Developer of human mesenchymal stem cells and extracellular vesicles. The company specializes in human bone marrow-derived and adipose-derived MSCs and associated, highly-engineered media formulations for the expansion of these cells. Founded in 2012, headquartered in Frederick, United States. The company has raised $38.4M in funding at the series b stage. The team comprises 58 (Jun 30, 2026) employees. RoosterBio operates in the Life Sciences Platforms and Tools, Cell Therapy, Genomics sectors. The company focuses on Bioreagents, Cell Culture. Notable investors include Maryland Stem Cell Research Fund, Vanedge Capital, Dynamk Capital, Planetary Technologies, HHS, TEDCO. The company has a team of 58 employees.
← All startups
RoosterBio
Series BDeveloper of human mesenchymal stem cells and extracellular vesicles. The company specializes in human bone marrow-derived and adipose-derived MSCs and associated, highly-engineered media formulations for the expansion of these cells. Founded in 2012, headquartered in Frederick, United States. The company has raised $38.4M in funding at the series b stage. The team comprises 58 (Jun 30, 2026) employees. RoosterBio…
About
Business model
Genomics > Enabling Technologies > Kits and Reagents > Bioreagents,
Life Sciences Platforms and Tools > Research Reagents and Kits > Cell Culture
Institutional investors
Maryland Stem Cell Research FundVanedge CapitalDynamk CapitalPlanetary TechnologiesHHSTEDCO
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.